These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 17683977

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Resistance to targeted therapy in chronic myelogenous leukemia.
    Hochhaus A, Erben P, Ernst T, Mueller MC.
    Semin Hematol; 2007 Jan; 44(1 Suppl 1):S15-24. PubMed ID: 17292737
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
    Cang S, Liu D.
    J Hematol Oncol; 2008 Oct 01; 1():15. PubMed ID: 18828913
    [Abstract] [Full Text] [Related]

  • 27. Flying under the radar: the new wave of BCR-ABL inhibitors.
    Quintás-Cardama A, Kantarjian H, Cortes J.
    Nat Rev Drug Discov; 2007 Oct 01; 6(10):834-48. PubMed ID: 17853901
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Applying the discovery of the Philadelphia chromosome.
    Sherbenou DW, Druker BJ.
    J Clin Invest; 2007 Aug 01; 117(8):2067-74. PubMed ID: 17671641
    [Abstract] [Full Text] [Related]

  • 30. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S, Zhang B, Cunnick JM, Heisterkamp N, Groffen J.
    Cancer Res; 2006 May 15; 66(10):5387-93. PubMed ID: 16707466
    [Abstract] [Full Text] [Related]

  • 31. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH, Tang JL, Chen RL, Li CC, Lee CP.
    Leuk Res; 2008 Nov 15; 32(11):1724-34. PubMed ID: 18603297
    [Abstract] [Full Text] [Related]

  • 32. [Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients].
    Qin YZ, Liu YR, Li JL, Ruan GR, Zhu HH, Jiang Q, Fu JY, Lu Y, Chang Y, Li LD, Huang XJ, Chen SS, Qiu JY.
    Zhonghua Yi Xue Za Zhi; 2005 Nov 30; 85(45):3186-9. PubMed ID: 16405837
    [Abstract] [Full Text] [Related]

  • 33. Imatinib resistance in CML.
    Volpe G, Panuzzo C, Ulisciani S, Cilloni D.
    Cancer Lett; 2009 Feb 08; 274(1):1-9. PubMed ID: 18653275
    [Abstract] [Full Text] [Related]

  • 34. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A, Prasad K.
    J Assoc Physicians India; 2007 Feb 08; 55():109-13. PubMed ID: 17571739
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. BCR-ABL in chronic myelogenous leukemia--how does it work?
    Goldman JM, Melo JV.
    Acta Haematol; 2008 Feb 08; 119(4):212-7. PubMed ID: 18566539
    [Abstract] [Full Text] [Related]

  • 38. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.
    Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD.
    Nat Rev Cancer; 2007 May 08; 7(5):345-56. PubMed ID: 17457302
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)].
    Tauchi T, Ohyashiki K.
    Gan To Kagaku Ryoho; 2003 Aug 08; 30(8):1065-70. PubMed ID: 12938259
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.